SHZ Healthcare Drug Manufacturers - Specialty & Generic 002004.SZ

Huapont Life Sciences Co., Ltd.

$ 4.12 -1.90 %

Huapont Life Sciences Co., Ltd. is a multifaceted company engaged in both the pharmaceutical and agrochemical industries, with operations spanning China and international markets. Its pharmaceutical arm is dedicated to the manufacture and distribution of medicinal preparations and their precursors. The company offers a broad range of healthcare products, including treatments for skin conditions, tuberculosis, infections, respiratory issues, cancer, and eye ailments, in addition to general wellness products. Within its agrochemical division, Huapont supplies technical pesticides, intermediates, and finished products, alongside providing technical services for GLP registration. Founded in 2001 and based in Chongqing, China, the company adopted its current name, Huapont Life Sciences Co., Ltd., in September 2015, having previously been known as Huapont-Nutrichem Co., Ltd. It was formerly a subsidiary of Huipont Tourism Co. Ltd.

CEO: Hai An Zhang - https://www.huapont.com.cn

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

-

DCF

$ 23.48

Loading data...

002004.SZ vs S&P500

Loading data...

No data available.

Quick ratio

1.18

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

11.77

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

0.35

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

6.83 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

3.39 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

4.85

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.84

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

0.89

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

28.17 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
8 indicates good financial health
Altman score
1.16 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.45 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.29 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.